Will New Drugs Replace Transplants for Chronic Lymphocytic Leukaemia?

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Hematopoietic stem cell transplantation (HSCT) has been a treatment for chronic lymphocytic leukemia (CLL) for over 35 years.
• Its application has been limited to a small fraction of highly selected patients, often those refractory to conventional therapies.

Purpose of the Study:

• To review the evolving role, techniques, and outcomes of HSCT in CLL.
• To discuss the mechanisms of anti-leukemic effects and prognostic factors associated with transplantation.
• To evaluate the current place of HSCT for CLL in the era of novel targeted therapies.

Main Methods:

• Review of existing data and literature on HSCT for CLL.
• Analysis of transplant-related morbidity and mortality.
• Discussion of anti-leukemic mechanisms (drugs, radiation, immune effects).

Main Results:

• HSCT can achieve long-term leukemia-free survival in select CLL patients.
• Transplantation is associated with significant treatment-related complications and mortality.
• Evolving CLL therapies impact transplant indications and techniques.

Conclusions:

• HSCT remains a potentially curative option for a subset of CLL patients.
• Careful selection of candidates is crucial due to substantial risks.
• The role of HSCT must be re-evaluated alongside new targeted drugs for CLL management.